Current Pharmacogenomics and Personalized Medicine
Title:Editorial (End of the Beginning and Public Health Pharmacogenomics: Knowledge in ‘Mode 2’ and P5 Medicine)
Volume: 10 Issue: 1
Author(s): Vural Ozdemir, Erik Fisher, Edward S. Dove, Hilary Burton, Galen E. B. Wright, Mario Masellis and Louise Warnich
Affiliation:
Keywords: Africa, global personalized medicine, knowledge in mode 2, omics biotechnologies, P5 medicine, public health pharmacogenomics, science studies, sociomateriality
Export Options
About this article
Cite this article as:
Ozdemir Vural, Fisher Erik, S. Dove Edward, Burton Hilary, E. B. Wright Galen, Masellis Mario and Warnich Louise, Editorial (End of the Beginning and Public Health Pharmacogenomics: Knowledge in ‘Mode 2’ and P5 Medicine), Current Pharmacogenomics and Personalized Medicine 2012; 10 (1) . https://dx.doi.org/10.2174/1875692111201010001
DOI https://dx.doi.org/10.2174/1875692111201010001 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acute Lymphoblastic Leukemia and Regulatory T cells: Biomarkers and Immunopathogenesis
Current Immunology Reviews (Discontinued) Case-Report: Folfoxiri Plus Bevacizumab in “Poor-Risk” Liver-Only Metastatic Colorectal Cancer: Case Report and State-of-the-Art
Clinical Cancer Drugs Medical Applications of Collagen and Collagen-Based Materials
Current Medicinal Chemistry MicroRNA Polymorphisms, MicroRNA Pharmacogenomics and Cancer Susceptibility
Current Pharmacogenomics and Personalized Medicine STAT Inhibition in the Treatment of Cancer: Transcription Factors as Targets for Molecular Therapy
Current Cancer Therapy Reviews Interaction of Wharton's Jelly Derived Fetal Mesenchymal Cells with Tumor Cells
Current Stem Cell Research & Therapy Cytochrome P450 Retinoic Acid 4-Hydroxylase Inhibitors: Potential Agents for Cancer Therapy
Mini-Reviews in Medicinal Chemistry Editorial [ Natural Products and Colon Drug Delivery ]
Current Drug Delivery Assessment of Adverse Drug Reaction Due to Cancer Chemotherapy in a Teaching Oncology Hospital in Isfahan, Central of Iran
Reviews on Recent Clinical Trials Protective Effects of Curcumin Against Nephrotoxic Agents
Cardiovascular & Hematological Disorders-Drug Targets Editorial [Hot Topic:Novel Targets in Cancer Therapy(Guest Editor: Debabrata Banerjee)]
Current Pharmaceutical Biotechnology Focused Microarray Analysis: Characterization of Phenomes by Gene Expression Profiling
Current Pharmacogenomics Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry The Chlorophyll Catabolite Pheophorbide a as a Photosensitizer for the Photodynamic Therapy
Current Medicinal Chemistry Toxicological Profile of Therapeutic Nanodelivery Systems
Current Drug Metabolism Ovarian Cancer Biomarkers: Headway Towards Early Diagnosis
Current Chemical Biology Naturally Occurring Hydroxytyrosol: Synthesis and Anticancer Potential
Current Medicinal Chemistry Applications of Lipid-based Nanocarriers for Parenteral Drug Delivery
Current Medicinal Chemistry Protein Kinases as Drug Targets in Cancer
Current Cancer Drug Targets Solid Lipid Nanoparticles: A Potential Approach for Drug Delivery System
Nanoscience & Nanotechnology-Asia